GlobeNewswire Inc | Jan 21, 2021 07:00AM EST

January 21, 2021

WALTHAM, Mass., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals,Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will host a virtual investor event titled Pegcetacoplan: Advancing the First Potential Treatment for Geographic Atrophy (GA) from10:00 a.m. to noon ET on January 28, 2021. The virtual meeting will focus on the significant unmet need in GA and the companys intravitreal pegcetacoplan program, which is on track for Phase 3 GA results in the third quarter of 2021.

Apellis management team will be joined by the following leading retinal physicians:

-- Caroline R. Baumal, M.D., Professor of Ophthalmology, Tufts Medical Center, New England Eye Center, Retina Department -- Nancy M. Holekamp, M.D., Director, Retina Services, Pepose Vision Institute -- Jeffrey S. Heier, M.D., Director, Retina Service, Ophthalmic Consultants of Boston -- Pearse A. Keane,M.D., Consultant Ophthalmologist,Moorfields Eye Hospital NHSFoundation Trust; Associate Professor, UniversityCollege London

The live webcast and slide presentation will be available from the Events and Presentations page of the Investors and Media section of the companys website at https://investors.apellis.com/events-and-presentations. To access the event via phone, please dial (833) 353-0413 (local) or (720) 405-3208 (international) at least 10 minutes prior to the start time and refer to conference ID 1162057. A replay of the webcast will be available for 90 days following the event.

About ApellisApellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, we aim to develop transformative therapies for a broad range of debilitating diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology. For more information, please visit www.apellis.com.

Forward-Looking StatementsStatements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements in respect of the expected closing of the exchanges. The words anticipate, believe, continue, could, estimate, expect, intend, may, plan, potential, predict, project, should, target, will, would and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether the conditions for the closing of the exchanges will be satisfied and other factors discussed in the Risk Factors section of Apellis Quarterly Report on Form 10-Q filed with theSecurities and Exchange Commissionon November 2, 2020and the risks described in other filings that Apellis may make with theSecurities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Apellis specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Contact:Argot Partnersapellis@argotpartners.com+1212.600.1902

Media:Tracy Vineismedia@apellis.com+1 617 420 4839